Intertek opens new UK bioanalytical facility

Skip to Navigation


  • Published: Sep 24, 2015
  • Author: Jon Evans
  • Channels: HPLC / Electrophoresis / Ion Chromatography / Proteomics & Genomics / Detectors / Sample Preparation / Gas Chromatography / Laboratory Informatics / Atomic / Raman / MRI Spectroscopy / Infrared Spectroscopy / Chemometrics & Informatics / Base Peak / NMR Knowledge Base / UV/Vis Spectroscopy / Proteomics / X-ray Spectrometry

The UK testing and inspection company Intertek has opened a new 10,000 ft2 bioanalytical and biopharmaceutical characterization facility to support the growing pipeline of biologics medicines such as monoclonal antibodies currently in development by clients around the globe.

This new facility will be based at Intertek’s Centre of Excellence for Biologics in Manchester, UK, expanding the centre’s capacity to 30,000 ft2 of analytical and bioanalytical laboratories. The new bioanalysis, immunogenicity and characterization capability will help drug companies ensure that biologics medicines such as monoclonal antibodies (mAbs), recombinant proteins and vaccines are safe and effective for treating heart disease, cancer-related diseases such as leukemia or melanoma, and other chronic ailments.

‘Intertek is highly committed to helping our clients to navigate the many technical challenges associated with bringing a biological medicine to market,’ said Chetan Parmar, senior vice president of Intertek Life Sciences. ‘This investment is key to providing the level of resource required to meet the ever increasing demand for our expertise and experience. Among the exciting projects now starting at this lab is testing of novel monoclonal antibody therapeutics, as well as antibody drug conjugates, which are highly complex yet offer great potential for a range of difficult-to-treat cancers.’

‘We are seeing a growing demand for contract safety and efficacy services for innovative antibody therapeutics which address previously un-met medical needs,’ said Ashleigh Wake, Intertek Biopharmaceutical services leader. ‘There is also demand for comparability and characterization testing services for numerous monoclonal antibody biosimilars which are on the cusp of being launched over the next few years, as patents on drugs such as infliximab, trastuzumab and rituximab are set to expire in the US.’

‘The impressive new Intertek laboratory underlines the importance of the Northern Powerhouse to the UK’s life sciences industry, which has already seen £3.5 billion of investment and the creation of 11,000 jobs since the Prime Minister launched the UK Strategy for Life Sciences in 2011,’ commented George Freeman, life sciences minister in the UK government. ‘With its ability to bring 21st century medicines one step closer to NHS patients, this facility can drive the innovation and growth of the future, putting life sciences in the north-west firmly on the map.’

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2019 John Wiley & Sons, Inc. All Rights Reserved